不同剂型硝苯地平治疗高血压的药物经济学评价

Pharmacoeconomic Evaluation of Nifedipine with Different Dosage forms for hypertension

目的评价抗高血压药硝苯地平临床常用三种不同剂型治疗高血压的临床效果和经济效益。方法选择90例高血压病患者随机分为三组,每组30例,分别口服硝苯地平普通片、缓释片和控释片治疗,并进行药物经济学分析。结果服药8周后各组患者血压均有明显下降,其中普通片、缓释片和控释片治疗高血压总有效率分别为93.33%、93.33%、96.66%,不良反应发生率分别为10.0%、6.6%、0.0%,成本-效果比分别为0.02、0.40、2.96,控释片相对于普通片的增量成本-效果比为85.43。结论硝苯地平缓释片虽其消费成本不是最低,但服法简单,副作用较少,综合评价是硝苯地平临床常用三种剂型治疗高血压的最佳剂型,特别适用于基层医院。

Objective To evaluate the therapeutic and economical efficacies of nifedipine with different dosage forms for hypertension. Methods In 90 patients with essential hypertension were randomly divided into three groups 30 cases in each group, respectively, oral administration of nifedipine sustained-release tablets and conventional tablets, controlled-release tablets, and pharmacoeconomic analysis. Results Both groups were significantly decreased blood pressure medication after 8 weeks, in which ordinary tablets, sustained-release tablets and controlled release tablets in treatment of hypertension and the total effective rate were 93.33%, 93.33%, 96.66%, the incidence of adverse reaction were 10.0%, 6.6%, 0.0%, the cost-effectiveness ratios were 0.02, 0.40, 2.96, controlled-release tablets compared with incremental cost - common tablets effect ratio is 85.43. Conclusion Nifedipine sustained-release tablets was proved to be the optimal dosage form hypotensive therapy among the 3 drugs, which thus deserved to be used preferably in primary level hospitals.